Is Livzon Pharmaceutical Group profitable in 2026?

Yes. Trailing twelve month figures as of 2026-07-15 show revenue of HKD 13.56bn and net income of HKD 2.27bn, per FT data. Q1 2026 net income was CNY 269.15 million, though it missed analyst revenue forecasts of CNY 3.47bn.

Who owns Livzon Pharmaceutical Group?

Livzon is controlled by Joincare Pharmaceutical Group Industry Co., Ltd., which held 45.23% of shares as of 2025-12-31. Livzon itself dual-lists as A-shares (SZSE 000513, since 1993) and H-shares (HKEX 1513).

Could AI replace Livzon Pharmaceutical Group?

No. Livzon's business rests on NMPA drug approvals, GMP manufacturing licenses, and hospital-tender relationships that AI does not replicate. As of mid-2026, AI shows up only as back-office quality-control and manufacturing-efficiency tooling industry-wide, not as a direct threat to its regulated drug business.

Is Livzon Pharmaceutical Group growing?

Growth is flat to negative. FY2024 revenue fell 6.70% year over year to RMB 12.70bn, and five year CAGR through FY2024 was only about 1.68%. Q1 2026 revenue of CNY 2.87bn came in below the CNY 3.47bn analyst forecast.

What did Livzon Pharmaceutical Group acquire in Vietnam?

In May 2026 Livzon, via subsidiary Lian SGP Holding, completed acquisition of a 67.87-67.88% controlling stake in Vietnam's Imexpharm Corporation (HoSE: IMP) from SK Group and other sellers for roughly USD 221-228 million.

Who is Livzon Pharmaceutical Group's biggest competitor?

Sinopharm Group, China's largest state-owned pharmaceutical distributor and manufacturer, dwarfs Livzon in scale. Domestically Livzon also competes with Hengrui Medicine, CSPC, Sino Biopharm and Fosun Pharma across generics, biosimilars and TCM products.

Pharma and healthcare groups · subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd. · China

Livzon Pharmaceutical Group

40-year-old Chinese pharma maker selling generics, biologics, and diagnostics via hospital tenders.

Defensible for now

Assessed 26 July 2026 · Evidence as of 26 July 2026

Real protection, with named pressure against it.

On the recordSince 26 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: H1 2026 results plus first integration update on the Imexpharm (Vietnam) acquisition

The call

Livzon keeps its regulatory footing and hospital ties intact while flat sales, price controls, and a fresh Vietnam integration test whether it can grow again.

Livzon makes and sells pharmaceutical drugs in China and recently bought a Vietnamese drug company. The company is hard to replace because it has government approvals and relationships with hospitals, but those protections do not help it grow. Right now its sales are flat or falling, and it faces heavy price pressure from the Chinese government's bulk-buying system and competition from bigger rivals like Sinopharm and Hengrui. The one thing that matters most is whether the new Vietnamese acquisition actually works out or becomes a costly mistake.

Why

AI pressure: None apparent. AI shows up as internal QC and process-optimization tooling here, not as a product that steals Livzon's customers. Could AI do the core job? Unlikely.

Bigger players: Sinopharm Group, plus peers Hengrui, CSPC, Sino Biopharm, Fosun Pharma. Bigger state-backed distributors and peer manufacturers already compete for the same hospital tenders and VBP-listed drug categories. Could a giant copy it? Probably.

What protects it. Decades of NMPA approvals, GMP-certified plants, and hospital-tender relationships that a new entrant cannot fast-track.

What would change this call

Livzon's H2 2026 results showing Imexpharm's Vietnam revenue contribution and integration costs. Whether the Vietnam acquisition offsets stagnant domestic China sales or drains cash.
Next Volume-Based Procurement tender round results for Livzon's fertility and GI drug lines. Whether pricing pressure from state procurement further erodes margins versus rivals.
NMPA regulatory decision on brexpiprazole microspheres or JP-1366. Whether new pipeline approvals can offset flat core revenue growth.

Key numbers

FY2024 revenue fell 6.7 percent (FY2024)
5-year revenue CAGR of just 1.68 percent (2024)
Imexpharm stake acquisition cost about USD 225 million (May 2026)

Named risks

China's Volume-Based Procurement pricing regime compresses margins on generics and biosimilars. Severity: high
Integration of newly acquired Imexpharm (Vietnam) stake, completed only May 2026, carries governance and cross-border compliance risk. Severity: medium
Flat to declining core revenue (FY2024 -6.70%, Q1 2026 missed forecasts) limits growth upside. Severity: medium
Regulatory dependency on NMPA approvals and hospital-tender access for future product launches. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Sinopharm Group	contesting	state-owned distributor/manufacturer far larger in scale, adjacent to Livzon's China market as of 2026
Jiangsu Hengrui Medicine	gaining on	cited as a more innovation-driven peer while Livzon's revenue fell 6.7% in FY2024
CSPC Pharmaceutical Group	gaining on	named peer in China pharma rankings amid Livzon's flat 1.68% five year revenue CAGR
Sino Biopharmaceutical	gaining on	listed alongside Livzon as a China-pharma comparator as of 2026-02
Fosun Pharma	contesting	overlapping biologics and diagnostics segments in the same domestic peer set

Questions people ask

Is Livzon Pharmaceutical Group profitable in 2026?: Yes. Trailing twelve month figures as of 2026-07-15 show revenue of HKD 13.56bn and net income of HKD 2.27bn, per FT data. Q1 2026 net income was CNY 269.15 million, though it missed analyst revenue forecasts of CNY 3.47bn.
Who owns Livzon Pharmaceutical Group?: Livzon is controlled by Joincare Pharmaceutical Group Industry Co., Ltd., which held 45.23% of shares as of 2025-12-31. Livzon itself dual-lists as A-shares (SZSE 000513, since 1993) and H-shares (HKEX 1513).
Could AI replace Livzon Pharmaceutical Group?: No. Livzon's business rests on NMPA drug approvals, GMP manufacturing licenses, and hospital-tender relationships that AI does not replicate. As of mid-2026, AI shows up only as back-office quality-control and manufacturing-efficiency tooling industry-wide, not as a direct threat to its regulated drug business.
Is Livzon Pharmaceutical Group growing?: Growth is flat to negative. FY2024 revenue fell 6.70% year over year to RMB 12.70bn, and five year CAGR through FY2024 was only about 1.68%. Q1 2026 revenue of CNY 2.87bn came in below the CNY 3.47bn analyst forecast.
What did Livzon Pharmaceutical Group acquire in Vietnam?: In May 2026 Livzon, via subsidiary Lian SGP Holding, completed acquisition of a 67.87-67.88% controlling stake in Vietnam's Imexpharm Corporation (HoSE: IMP) from SK Group and other sellers for roughly USD 221-228 million.
Who is Livzon Pharmaceutical Group's biggest competitor?: Sinopharm Group, China's largest state-owned pharmaceutical distributor and manufacturer, dwarfs Livzon in scale. Domestically Livzon also competes with Hengrui Medicine, CSPC, Sino Biopharm and Fosun Pharma across generics, biosimilars and TCM products.

Timeline

2026-07-24Receives China drug registration certificate for decoction granules for phlegm
2026-06-01NMPA approves biosimilar fertility drug Li You Bao via Livzon MABPharm
2026-05-11Completes controlling stake acquisition of Vietnam's Imexpharm Corporation
2026-05Liu Daping appointed President and Executive Director
2025-10-23Q3 2025 report shows 15,376,845 A-shares repurchased under buyback program
2025-03-26Contributes RMB 1bn capital to biologics subsidiary LivzonBio
2023-12First approval of Livzon's COVID-19 recombinant fusion-protein vaccine
1993-10-28Completes A-share listing on Shenzhen Stock Exchange (000513)
1985-01-26Company incorporated and registered in Zhuhai, Guangdong

Revision history

26 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Zoetis Boston Scientific Becton Dickinson

More in Pharma and healthcare groups →